|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||53.58 - 55.92|
|52-week range||41.30 - 66.86|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||N/A|
|Earnings date||24 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||63.27|
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.
Mechelen, Belgium; 6 May 2022, 22.01 CET; regulated information –– Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 2,326,025 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 6 May 2022, the board of directors of Galapagos approved “Subscription Right Plan 2022 BE”, intended for members of personnel of the company and its Belgian subsidiary, “Subscription Ri